Ivora Consulting

Ivora ConsultingIvora ConsultingIvora Consulting

Ivora Consulting

Ivora ConsultingIvora ConsultingIvora Consulting
  • Home
  • About
  • Publications and Patents
    • Publications
    • Patents
    • Presentations
  • Contact
  • More
    • Home
    • About
    • Publications and Patents
      • Publications
      • Patents
      • Presentations
    • Contact
  • Home
  • About
  • Publications and Patents
    • Publications
    • Patents
    • Presentations
  • Contact

Peer-reviewed Publications

Publications

  

  1. “Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate  Dehydrogenase 1-Mutant Malignancies.” Chen, Y.; Nagaraja, N. V.; Fan, B.; Utley, L.; Lemieux, R. M.; Popovici-Muller, J.; Dang, L.; Kim,  H.; Yan, L.; Su, S-S.; Biller, S. A.; Yang, H. Drug Metabolism and Disposition 2021, 49, 870-881.
  2. “Preclinical toxicology profile of squalene epoxidase inhibitors.” Nagaraja, R.; Olaharski, A.; Narayanaswamy, R.; Mahoney, C.; Pirman, D.; Gross, S.; Roddy, T. P.; Popovici-Muller, J.; Smolen, G. A.; Silverman, L. Toxicology and Applied Pharmacology 2020, 401, 115103.
  3. "Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma." Konteatis, Z.; Artin,  E.; Nicolay, B.; Straley, K.; Padyana, A.; Jin, L.; Chen, Y.; Narayaraswamy, R.; Tong, S.; Wang, F.; Zhou, D.; Cui, D.; Cai, Z.; Luo, Z.; Fang, C.;  Tang, H.; Lv, X.; Nagaraja, R.; Yang, H.; Su, S-S; Sui, Z.; Dang, L.; Yen, K.; Popovici-Muller, J.; Codega, P.; Campos, C.; Mellinghoff, I.; Biller, S.  ACS Medicinal Chemistry Letters 2020, 11(2), 101-107.
  4. “Structure and inhibition mechanism of the catalytic domain of human squalene epoxidase.” Padyana, A. K.; Gross, S.; Jin, L.; Cianchetta, G.; Narayanaswamy, R.; Wang, F.; Wang,      R.; Fang, C.; Lv, X.; Biller, S. A.; Dang, L.; Mahoney, C. E.; Nagaraja, N.; Pirman, D.; Sui, Z.; Popovici-Muller, J.; Smolen, G. A.;  Nature  Communications 2019, 10, 97, 1-10.
  5. “A  chemical biology screen identifies a vulnerability of neuroendocrine cancer cells to SQLE inhibition.” Mahoney, C. E.; Pirman, D.; Chubukov, V.; Sleger, T.; Hayes, S.; Fan, Z. P.; Allen, E.L.; Chen, Y.; Huang, L.; Liu, M.; Zhang, Y.; McDonald, G.; Narayanaswamy, R.; Choe, S.; Chen, Y.; Gross, S.; Cianchetta, G.; Padyana, A. K.; Murray, S.; Liu, W.; Marks, K. M.; Murtie, J.; Dorsch, M.; Jin, S.; Nagaraja, N.; Biller, S. A.; Roddy, T.; Popovici-Muller, J.; Smolen, G. A.; Nature Communications 2019, 10, 96, 1-14.
  6. “AG-348 enhances pyruvate kinase activity in red blood cells from patients with      pyruvate kinase deficiency.” Kung, .; Hixon, J.; Kosinski, P. A.; Cianchetta, G.; Histen, G.; Chen, Y.; Hill, C.; Gross, S.; Si, Y.; Johnson, K.; De La Barre, B.; Luo, Z.; Gu, Z.; Yao, G.; Tang, H.; Fang,      C.; Xu, Y.; Lv, X.; Biller, S.; Su, M.; Yang, H.; Popovici-Muller, J.; Salituro, F.; Silverman, L.; Dang, L.;  Blood 2017, 130, 1347-1356.
  7. “Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the      Treatment of IDH1 Mutant Cancers.” Popovici-Muller, J.; Lemieux, R. M.; Artin, E.; Saunders, J. O.; Salituro, F.      G.; Travins, J.; Cianchetta, G.; Cai, Z.; Zhou, D.; Cui, D.; Chen, P.; Straley, K.; Tobin, E.; Wang, F.; David, M. D.; Penard-Lacronique, V.;  Quivoron, C.; Saada, V.; de Botton, S.; Gross, S.; Dang, L.; Yang, H.; Utley, L.; Chen, Y.; Kim, H.; Jin, S.; Gu, Z.; Yao, G.; Luo, Z.; Lv, X.;  Fang, C.; Yan, L.; Olaharski, A.; Silverman, L.; Biller, S.; Su, M.; Yen,  K.;  ACS Medicinal Chemistry Letters 2018, 9, 300-305.
  8. “Fused bi-heteroaryl substituted hydantoin compounds as TACE  inhibitors.” Tong, L.; Kim, S.H.; Rosner, K.; Yu, W.; Shankar, B.; Chen, L.; Li, D.; Dai, C.; Girijavallabhan, V.; Popovici-Muller, J.; Yang, L.; Zhou, G.; Kosinski, A.; Siddiqui, M. A.; Shih, N-Y.; Guo, Z.; Orth, P.; Chen, S.; Lundell, D.;  Niu, X.; Umland, S.; Kozlowski, J. A.;  Bioorganic & Medicinal Chemistry Letters 2017, 27, 3037-3042.
  9. “Mutant IDH inhibits  HNF-4α to block hepatocyte differentiation and promote biliary cancer.”      Saha, S. K; Parachoniak, C. A; Ghanta, K. S; Fitamant, J.; Ross, K. N.;  Najem, M. S.; Gurumurthy, S.; Akbay, E. A; Sia, D.; Cornella, H.; Miltiadous, O.; Walesky, C.; Deshpande, V.; Zhu, A. X.; Hezel, A. F.; Yen,  K. E.; Straley, K. S.; Travins, J.; Popovici-Muller, J.; Gliser, C.; Ferrone, C. R; Apte, U.; Llovet, J. M.; Wong, K-K.; Ramaswamy, S.; Bardeesy, N. Nature, 2014, 513, 110-114.
  10. “Biochemical, Cellular, and Biophysical Characterization of a Potent Inhibitor of Mutant      Isocitrate Dehydrogenase IDH1.” Davis, M. I.; Gross, S.; Shen, M.; Straley, K. S.; Pragani, R.; Lea, W. A.; Popovici-Muller, J.; De La Barre, B.; Artin, E.; Thorne, N.;  Auld, D. S.; Li, Z.; Dang, L.; Boxer, M. B.; Simeonov, A. Journal of Biological Chemistry, 2014, 289,  13717-13725.
  11. “The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitors.” Labroli, M.      A.; Dwyer, M. P.; Shen, R.; Popovici-Muller, J.; Pu, Q.; Wyss, D.; McCoy, M.; Barrett, D.; Davis, N.; Seghezzi,  W.; Shanahan, F.; Taricani, L.; Beaumont, M.; Malinao, M-C.; Parry, D.; Guzi, T. J. Bioorganic & Medicinal Chemistry 2014, 22, 2303-2310.
  12. “Syntheses of 5'-amino-2',5'-dideoxy-2',2'-difluorocytidine derivatives as novel anticancer nucleoside analogs.” Labroli, M. A.; Dwyer, M. P.; Shen, R.; Popovici-Muller, J.; Pu, Q.; Richard, J.; Rosner, K.; Paruch, K.; Guzi, T. J. Tetrahedron Letters 2014, 55, 598-602.
  13. “Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor. “      Deng, Y.; Shipps, G. W., Jr.; Zhao, L.; Siddiqui, M. A.; Popovici-Muller, J.; Curran, P. J.; Duca, J. S.; Hruza, A. W.; Fischmann, T. O.;  Madison, V. S.; Zhang, R.; McNemar, C. W.; Mayhood, T. W.; Syto, R.;  Annis, A.; Kirschmeier, P.; Lees, E. M.; Parry, D. A.; Windsor, W. T. Bioorganic & Medicinal Chemistry  Letters 2014, 24, 199-203.
  14. “An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells.“ Rohle, D.; Popovici-Muller, J.; Palaskas, N.; Turcan, S.; Grommes, C.; Campos, C.; Tsoi, J.;      Clark, O.; Oldrini, B.; Komisopoulou, E.; Kunii, K.; Pedraza, A.; Schalm, S.; Silverman, L.; Miller, A.; Wang, F.; Yang, H.; Chen, Y.; Kernytsky,  A.; Rosenblum, M. K.; Liu, W.; Biller, S. A.; Su, S. M.; Brennan, C. W.;  Chan, T. A.; Graeber, T. G.; Yen, K. E.; Mellinghoff, I. K. Science, 2013, 340, 626-630.
  15. “Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation.“ Wang, F.; Travins, J.; De La Barre, B.; Penard-Lacronique, V.; Schalm, S.; Hansen, E.; Straley, K.; Kernytsky, A.; Liu, W.; Gliser, C.; Yang, H.; Gross, S.; Artin, E.; Saada, V.; Mylonas, E.; Quivoron, C.; Popovici-Muller, J.; Saunders, J. O.; Salituro, F. G.; Yan, S.; Murray, S.; Wei, W.; Gao, Y.; Dang, L.; Dorsch,      M.; Agresta, S.; Schenkein, D. P.; Biller, S. A.; Su, S. M.; de Botton,  S.; Yen, K. E. Science, 2013, 340, 622-626.
  16. “Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo .“ Popovici-Muller, J.; Saunders, J. O.; Salituro, F. G.; Travins, J. M.; Yan, S.; Zhao, F.; Gross, S.; Dang, L.; Yen, K. E.; Yang, H.; Straley, K. S.; Jin, S.; Kunii, K.; Fantin, V. R.; Zhang, S.; Pan, Q.; Shi, D.; Biller, S. A.; Su, S. M. ACS Medicinal Chemistry Letters 2012, 3, 850-855.
  17. “2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors. “ Dai, C.; Li, D.; Popovici-Muller, J.; Zhao, L.; Girijavallabhan, V. M.; Rosner, K. E.; Lavey, B. J.; Rizvi, R.; Shankar, B. B.; Wong, M. K. C.; Guo, Z.; Orth, P.; Strickland, C. O.; Sun, J.; Niu, X.; Chen, S.; Kozlowski, J. A.; Lundell, D. J.; Piwinski, J. J.; Shih, N-Y; Siddiqui, M. A. Bioorganic & Medicinal Chemistry Letters 2011, 21, 3172-3176.
  18. “Novel TNF-α converting  enzyme (TACE) inhibitors as potential treatment for inflammatory      diseases.“ Girijavallabhan, V. M.; Chen, L.; Dai, C.; Feltz, R. J.; Firmansjah, L.; Li, D.; Kim, S. H.; Kozlowski, J. A.; Lavey, B. J.;  Kosinski, A.; Piwinski, J. J.; Popovici-Muller, J.; Rizvi, R.; Rosner, K. E.; Shankar, B. B.; Shih, N-Y; Siddiqui, M. A.; Tong, L.; Wong, M. K. C.; Yang, D-Y.; Yang, L.; Yu, W.; Zhou, G.; Guo, Z.; Orth, P.; Madison, V.; Bian, H.; Lundell, D.; Niu, X.; Shah, H.; Sun, J.; Umland, S. Bioorganic & Medicinal Chemistry  Letters 2010, 20, 7283-7287.
  19. “Structure and activity relationships of tartrate-based TACE inhibitors.“ Li, D.; Popovici-Muller,      J.; Belanger, D. B.; Caldwell, J.; Dai, C.;  David, M.; Girijavallabhan, V.M.; Lavey, B. J.; Lee, J. F.; Liu, Z.;  Mazzola, R.; Rizvi, R.; Rosner, K. E.; Shankar, B.; Spitler, J.; Ting, P. C.; Vaccaro, H..; Yu, W.; Zhou, G.; Zhu, Z.; Niu, X.; Sun, J.; Guo, Z.; Orth, P.; Chen, S.; Kozlowski, J. A.; Lundell, D.J.; Madison, V.; McKittrick, B.; Piwinski, J. J.; Shih, N-Y.; Shipps, G. W., Jr.; Siddiqui, M. A.; Strickland, C. O. Bioorganic  & Medicinal Chemistry Letters 2010, 20, 4812-4815.
  20. “Discovery and SAR of Hydantoin TACE Inhibitors.” Yu, W.;  Guo, Z.; Orth,  P.; Madison, V.; Chen, L.; Dai, C.; Feltz, R. J.; Girijavallabhan, V. M.;  Kim, S. H.; Kozlowski, J. A.; Lavey,  B. J.; Li,  D.; Lundell, D. J.; Niu,  X.; Piwinski, J. J.; Popovici-Muller, J.; Rizvi, R.; Rosner, K. E.; Shankar, B. B.; Shih, N.-Y.; Siddiqui,  M. A.; Su, J.; Tong, L.; Umland, S.; Wong, M. K. C.; Yang, D-Y.; Zhou, G. Bioorganic & Medicinal Chemistry Letters 2010, 20, 1877-1880.
  21. “The Discovery of Novel  Tartrate-based TNF-α  Converting Enzyme (TACE) Inhibitors.” Rosner, K. E.; Guo, Z.; Orth, P.; Shipps, G. W.  Jr.; Belanger,  D. B.; Chan,T. Y.; Curran, P. J.; Dai, C.; Deng, Y.; Girijavallabhan, V. M.;  Hong,  L.; Lavey, B. J.; Lee, J. F.; Li, D.; Liu, Z.; Popovici-Muller, J.; Ting, P. C.; Vaccaro, H.; Wang, L.; Wang,  T.; Yu, W.; Zhou, G.; Niu, X.; Sun, J.; Kozlowski, J. A.; Lundell, D. J.; Madison, V.; McKittrick, B.; Piwinski, J. J.; Shih, N.-Y.; Siddiqui, M. A.; Strickland, C. O. Bioorganic & Medicinal Chemistry Letters 2010, 20,  1189-1193.
  22. “Pyrazolo[1,5-a]pyrimidine-based Inhibitors of HCV Polymerase.” Popovici-Muller, J.; Shipps, G. W.; Rosner K. E.; Deng, Y.; Wang, T.; Curran, P. J.; Brown, M. A.; Siddiqui, M. A.; Cooper, A. B.; Duca, J.;  Cable, M.; Girijavallabhan, V. Bioorganic  & Medicinal Chemistry Letters 2009, 19, 6331-6336. 
  23. “Discovery of 4H-pyrazolo[1,5-a]pyrimidin-7-ones as potent inhibitors of hepatitis C  virus polymerase.” Deng, Y.; Shipps, G. W.; Wang, T.; Popovici-Muller, J.; Rosner K. E.; Siddiqui, M. A.; Duca, J.; Cooper, A. B.; Cable, M. Bioorganic & Medicinal Chemistry Letters 2009, 19, 5363-5367.
  24. “Method for Quantitative Protein-Ligand Affinity Measurements in Compound Mixtures.” Annis, D. A.;  Shipps, G. W. Jr; Deng, Y.; Popovici-Muller,  J.; Siddiqui, M. A.; Curran, P. J.; Gowen, M.; Windsor. W. T; Analytical chemistry 2007, 79 (12), 4538-4542.
  25. “Preparation  and biochemical evaluation of fluorenone-containing lipid analogs.” Spencer, T. A.; Wang, P.; Popovici-Muller, J. V.; Peltan, I. D.; Fielding, P. E.; Fielding, C. J. Bioorganic  & Medicinal Chemistry Letters 2006, 16, 3000-3004. 
  26. “Aminothiazole Inhibitors  of HCV RNA Polymerase.” Shipps, G. W.; Deng, Y.; Wang, T.; Popovici-Muller, J.; Curran, P. J.; Rosner K. E.; Cooper, A. B.; Girijavallabhan, V.; Butkiewicz, N.; Cable, M. Bioorganic  & Medicinal Chemistry Letters 2005, 15, 115-119.
  27. “The Singular Reduction of  1,8-bis-Hydroxymethynaphthalene to a Benzonorcaradiene by LiAlH4.” Popovici-Muller, J. V.; Spencer, T. A. Tetrahedron Lett. 1997, 38, 8161-8164.

Copyright © 2025 Ivora Consulting - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept